{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:49Z","timestamp":1792834729638,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system characterized by recurrent optic neuritis and longitudinally extensive transverse myelitis, frequently leading to severe and irreversible disability. Over the past decade, advances in diagnostic criteria, serological testing, and biomarker research have substantially transformed the diagnostic framework of NMOSD. However, a comprehensive bibliometric analysis focusing specifically on diagnostic research in this field has been lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Publications related to NMOSD diagnostic research published between 2016 and 2025 were retrieved from the Web of Science Core Collection. After refinement of the search strategy and manual screening based on predefined relevance criteria, bibliometric analyses were performed using CiteSpace, VOSviewer, and the Bibliometrix package in R to evaluate publication trends, international collaboration patterns, co-citation networks, and evolving research hotspots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 2029 publications were included. Annual publication output and citation counts increased steadily throughout the study period, reflecting sustained expansion of academic interest. China was the leading contributor, with strong collaborative links to the United States and the United Kingdom. The 2015 international consensus diagnostic criteria emerged as the most influential reference, serving as a foundational framework for subsequent research. Co-citation and keyword analyses demonstrated a clear shift from an early focus on disease definition and differential diagnosis toward biomarker-guided and technology-enabled precision diagnosis. Current research frontiers include optimization of aquaporin-4 immunoglobulin G detection platforms, astrocytic injury biomarkers such as glial fibrillary acidic protein, inflammatory mediators including interleukin-6 and complement components, magnetic resonance imaging\u2013 and optical coherence tomography\u2013based neuroimaging markers, and multimodal diagnostic assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>NMOSD diagnostic research has transitioned from consensus-driven classification toward integrated, multimodal precision strategies. Continued international collaboration and biomarker standardization will be essential to improve early diagnosis and clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050424","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:19Z","timestamp":1787968879000},"page":"e50424","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Global trends and emerging hotspots in neuromyelitis optica spectrum disorder diagnostic research"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5396-4851","authenticated-orcid":false,"given":"Siyu","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Neurology II, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9301-6359","authenticated-orcid":false,"given":"Yifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China"},{"name":"Department of Neurology, The Second Hospital of Hebei Medical University, The Key Laboratory of Neurology, Hebei Medical University, Ministry of Education, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-2321","authenticated-orcid":false,"given":"Yanqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum.","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica.","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"873576","DOI":"10.3389\/fimmu.2022.873576","article-title":"Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis.","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder.","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"912050","DOI":"10.3389\/fneur.2022.912050","article-title":"Testing for antibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in the diagnosis of patients with suspected autoimmune myelopathy.","volume":"13","author":"Alkabie","year":"2022","journal-title":"Front Neurol"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker.","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"e200531","DOI":"10.1212\/NXI.0000000000200531","article-title":"OCT-based differentiation of first acute optic neuritis: an international study of 111 patients with NMOSD and MOGAD.","volume":"13","author":"Pakeerathan","year":"2026","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/jnnp-2025-336694","article-title":"MRI lesion distribution criteria for MS, NMOSD and MOGAD differentiation: a systematic review and meta-analysis.","volume":"97","author":"Tseriotis","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder.","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/acn3.52310","article-title":"Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay.","volume":"12","author":"Said","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2023.2974","article-title":"Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder.","volume":"80","author":"Fu","year":"2023","journal-title":"JAMA Neurol"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1002\/acn3.52178","article-title":"Dried blood spot improves global access to aquaporin-4-IgG testing for neuromyelitis optica.","volume":"11","author":"Vorasoot","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica.","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40263-025-01260-x","article-title":"Consensus recommendations for the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD): the MENACTRIMS guidelines.","volume":"40","author":"Yamout","year":"2026","journal-title":"CNS Drugs"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"1135061","DOI":"10.3389\/fimmu.2023.1135061","article-title":"Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"1177127","DOI":"10.3389\/fimmu.2023.1177127","article-title":"Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis.","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"R23-20261024","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases.","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"R24-20261024","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"626502","DOI":"10.3389\/fphar.2020.626502","article-title":"Bibliometric analysis of the inflammasome and pyroptosis in brain.","volume":"11","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4103\/1673-5374.303032","article-title":"Research trends, hot spots and prospects for necroptosis in the field of neuroscience.","volume":"16","author":"Yan","year":"2021","journal-title":"Neural Regen Res"},{"key":"R27-20261024","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/nep3.70019","article-title":"Bibliometric analysis and core target identification of network pharmacology on neuroinflammation in central nervous system disorders: trends, collaborations, and future directions.","volume":"3","author":"Zhang","year":"2025","journal-title":"Neuroprotection"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients.","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"R29-20261024","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"R30-20261024","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease.","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"R32-20261024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review.","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"R33-20261024","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis.","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol"},{"key":"R34-20261024","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2013 from mechanisms to trials.","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"R35-20261024","doi-asserted-by":"crossref","first-page":"105434","DOI":"10.1016\/j.msard.2024.105434","article-title":"Predicting time to serologic diagnosis of AQP4+ NMOSD based on clinical factors and social determinants of health.","volume":"83","author":"Rotstein","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"R36-20261024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R37-20261024","doi-asserted-by":"crossref","first-page":"102218","DOI":"10.1016\/j.msard.2020.102218","article-title":"The 2015 IPND criteria increases the yield in diagnosis of neuromyelitis optica spectrum disorder in Thai patients compared to the 2006 diagnostic criteria.","volume":"43","author":"Rattanathamsakul","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R38-20261024","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jnnp-2024-334764","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.","volume":"96","author":"H\u00e4u\u00dfler","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R39-20261024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12865-025-00735-2","article-title":"Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis.","volume":"26","author":"Lin","year":"2025","journal-title":"BMC Immunol"},{"key":"R40-20261024","doi-asserted-by":"crossref","first-page":"e1110","DOI":"10.1212\/NXI.0000000000001110","article-title":"Demystifying MOGAD and double seronegative NMOSD further with IL-6 blockade.","volume":"9","author":"Yong","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R41-20261024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R42-20261024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00415-025-13249-z","article-title":"Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.","volume":"272","author":"Wang","year":"2025","journal-title":"J Neurol"},{"key":"R43-20261024","doi-asserted-by":"crossref","first-page":"17562864251345792","DOI":"10.1177\/17562864251345792","article-title":"Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGAD.","volume":"18","author":"Schindler","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"R44-20261024","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders.","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R45-20261024","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD.","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R46-20261024","doi-asserted-by":"crossref","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies.","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"R47-20261024","doi-asserted-by":"crossref","first-page":"106410","DOI":"10.1016\/j.msard.2025.106410","article-title":"The utility of serum neurofilament light chain in MOGAD: current insights and future directions.","volume":"98","author":"Labib","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"R48-20261024","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management.","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"R49-20261024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two central nervous system autoimmune inflammatory disorders.","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol Clin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:01:00Z","timestamp":1792832460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050424"}},"subtitle":["A bibliometric analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":49,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050424","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}